Wegovy pill sales hit DKK 5.39bn (about $810m) in Q3, up 53% on the previous quarter and ahead of forecasts, and Novo raised its full-year outlook for the third time. US injectable Wegovy sales fell 13%, though combined US Wegovy sales rose 21%.

Source: Reuters (via StreetInsider) (4 Nov 2026).

Older article: Novo Q3 report: Wegovy pill now in eight markets including the UK

Novo Q3 report: Wegovy pill now in eight markets including the UK4 Nov 2026
CNBC: Novo beats on Wegovy and Ozempic sales4 Nov 2026
GP warns Mounjaro and Wegovy users not to bin used needles4 Nov 2026
Retatrutide beats Ozempic in head-to-head Phase 3 diabetes trial3 Nov 2026

Retatrutide side effects: more discontinuations than Ozempic at top dose3 Nov 2026

RSS feed

Subscribe to the feedEvery published article, newest first

Novo Nordisk lifts 2026 outlook as Wegovy pill beats forecasts

Novo Nordisk lifts 2026 outlook as Wegovy pill beats forecasts

RSS feed

Categories